Xiuning Le

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6488852/publications.pdf

Version: 2024-02-01

53	3,019	257450 24	189892 50
papers	citations	h-index	g-index

55	55	55	3282
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tepotinib in Nonâ€“Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine, 2020, 383, 931-943.	27.0	500
2	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
3	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research, 2018, 24, 6195-6203.	7.0	292
4	Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature, 2021, 597, 732-737.	27.8	185
5	Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell, 2020, 37, 639-654.e6.	16.8	151
6	Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 205-215.	1.1	149
7	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell, 2019, 36, 444-457.e7.	16.8	145
8	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	1.1	109
9	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
10	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine, 2020, 12, .	12.4	101
11	Poziotinib in Nonâ€“Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. Journal of Clinical Oncology, 2022, 40, 710-718.	1.6	72
12	Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.. Journal of Clinical Oncology, 2020, 38, 9514-9514.	1.6	68
13	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62
14	Poziotinib for Patients With HER2 Exon 20 Mutant Nonâ€“Small-Cell Lung Cancer: Results From a Phase II Trial. Journal of Clinical Oncology, 2022, 40, 702-709.	1.6	53
15	Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clinical Cancer Research, 2022, 28, 1117-1126.	7.0	52
16	Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 779-792.	1.1	50
17	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Nonâ€“small-cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2019, 20, 43-47.	2.6	45
18	Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199297.	3.2	40

#	Article	IF	Citations
19	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. Journal of Thoracic Disease, 2018, 10, 3909-3921.	1.4	35
20	Î²-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. Journal of NeuroImmune Pharmacology, 2020, 15, 27-36.	4.1	35
21	Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 9052-9052.	1.6	35
22	Altered Regulation of HIF-1Î± in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. Journal of Thoracic Oncology, 2021, 16, 439-451.	1.1	34
23	Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clinical Lung Cancer, 2021, 22, 601-606.	2.6	31
24	INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncology, 2022, 18, 1039-1054.	2.4	30
25	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859.	5.9	29
26	Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined. Annals of Translational Medicine, 2018, 6, 229-229.	1.7	26
27	Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 899-906.	4.9	24
28	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	12.8	24
29	Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review. Clinical Lung Cancer, 2022, 23, 195-207.	2.6	22
30	Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Current Oncology Reports, 2020, 22, 31.	4.0	17
31	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Network Open, 2022, 5, e2215589.	5.9	15
32	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	4.2	14
33	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer, 2020, 149, 33-40.	2.0	12
34	New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer. Oncologist, 2020, 25, 822-825.	3.7	9
35	Heterogeneity in MET-Aberrant NSCLC. Journal of Thoracic Oncology, 2021, 16, 504-506.	1.1	9
36	Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Nonâ€“Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precision Oncology, 2021, 5, 1802-1812.	3.0	9

#	Article	IF	Citations
37	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clinical and Research Reports, 2021, 2, 100237.	1.1	8
38	Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx).. Journal of Clinical Oncology, 2022, 40, 9121-9121.	1.6	8
39	Emerging Therapies in Thoracic Malignanciesâ€"Immunotherapy, Targeted Therapy, and T-Cell Therapy in Nonâ€"Small Cell Lung Cancer. Surgical Oncology Clinics of North America, 2020, 29, 555-569.	1.5	6
40	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. Journal of Thoracic Oncology, 2021, 16, 2051-2064.	1.1	6
41	ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. Cancer Cell, 2021, 39, 1178-1180.	16.8	6
42	BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naÃ¯ve ALK-rearranged advanced NSCLC.. Journal of Clinical Oncology, 2020, 38, 9624-9624.	1.6	5
43	Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. Clinical Lung Cancer, 2022, 23, 320-332.	2.6	5
44	Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study. Cancer Research, 2022, 82, LB078-LB078.	0.9	4
45	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clinical Cancer Research, 2022, , .	7.0	3
46	Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head and Neck, 2021, 43, 1592-1603.	2.0	2
47	innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS6100-TPS6100.	1.6	2
48	Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping: Health-related quality of life (HRQoL).. Journal of Clinical Oncology, 2020, 38, 9575-9575.	1.6	1
49	Abstract CT536: Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC. Cancer Research, 2022, 82, CT536-CT536.	0.9	1
50	Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.. Journal of Clinical Oncology, 2022, 40, 9120-9120.	1.6	1
51	In Response. Journal of Thoracic Oncology, 2022, 17, e39.	1.1	0
52	Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic nonâ€"small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9055-9055.	1.6	0
53	Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e21169-e21169.	1.6	0